Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

En reell, multisenter, prospektiv, observasjonsstudie for PNH i Kina (ReWoPNH)

22. september 2026 oppdatert av: AstraZeneca

En reell, multisenter, prospektiv, observasjonsstudie for paroksysmal nattlig hemoglobinuri (PNH) i Kina

As a rare disease listed in the First Catalogue of Rare Diseases in China (National Health Commission of the People's Republic of China, 2019), PNH is poorly studied in China subse-quently leading to the inadequate elucidation of disease characteristics and clinical outcomes. Eculizumab was recently approved by NMPA. The availability of Eculizumab in China pro-vides people living with PNH with a new treatment option that can reduce disease symptoms and prevent the dysregulated complement system from causing further damage. A Phase Ⅳ study is necessary to understand the natural history of disease and the clinical outcomes with different medical interventions.

Studieoversikt

Status

Fullført

Detaljert beskrivelse

Paroxysmal nocturnal hemoglobinuria (PNH) is an ultra-rare and life-threatening acquired disorder of the pluripotent hematopoietic stem cell and therefore can affect erythrocytes, leukocytes, thrombocytes and probably some endothelial cells. These hematopoietic stem cells have acquired a somatic mutation in the phosphatidylinositol glycan class A (PIG-A) This gene is required for the synthesis of the glycosyl phosphatidyl-inositol (GPI) anchor, which is necessary to attach some proteins to the blood cell membrane. Therefore, a lack of two important complement regulatory proteins is observed on the cell surface: 'decay-accelerating factor' (DAF), also called 'CD55' and 'membrane inhibitor of reactive lysis' (MIRL), also called 'CD59' Thus, red blood cells are more vulnerable to the attack by the complement activation product MAC (complement membrane attack complex). This leads to a complement-mediated intravascular hemolysis. The predisposition of venous thrombosis, hemolytic anemia, complete thrombocytopenia, and thrombosis are the three main characteristics of the disease. Its incidence is not really known but estimated at 0.1~0.6/100 000 per-sons/yr, and prevalence is estimated at 1~4 cases/100,000 persons/yr. PNH was listed in the First Catalogue of Rare Diseases in China, and its incidence was previously reported to be 1/100,000 persons/year, peak onset age 20~40 years.

PNH can be classified into 3 different forms: classical PNH, PNH associated with aplastic anemia (PNH-AA), and subclinical PNH, based on clinical features, bone marrow characteristics, and the size of the mutant clone. The traditional treatment of PNH is still aimed at "protecting" the PNH clone, reducing complement attack and destruction, and alleviating hemolysis with symptomatic supportive therapy. In acute hemolytic episodes, could be administered adrenal glucocorticoids, complemented by cell membrane stabilizers, folic acid, and alkaline drugs. In case of PNH-AA syndrome, treatment with androgens and immunosuppressants may be used; anticoagulation and heparin therapy should be given for the occurrence of thrombosis; other symptomatic supportive treatments include transfusion of red blood cells and platelets if necessary as well as antibacterial drugs in case of infection. Bone marrow transplantation is the only curative therapy for PNH presupposes, but patient need to achieve complete remission with chemotherapy first and a suitable donor is needed.

Besides supportive care, global guidance/consensus also recommend C5 complement inhibitor Eculizumab as a treatment method, and its use could significantly improve 5-year survival rate to 95.5%. Eculizumabis a humanized, first-in-class, anti-C5 antibody that binds with high affinity to C5 and blocks the terminal complement-C5a and C5b-9 formation, reducing the chronic uncontrolled complement activation and its consequences. Eculizumab has been approved for PNH by National Medical Products Administration in August, 2022.

Studietype

Observasjonsmessig

Registrering (Faktiske)

724

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Hangzhou, Kina
        • Research Site
    • Anhui
      • Hefei, Anhui, Kina, 230002
        • Research Site
    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100000
        • Research Site
      • Beijing, Beijing Municipality, Kina, 100044
        • Research Site
    • Guangdong
      • Guangzhou, Guangdong, Kina, 510080
        • Research Site
      • Guangzhou, Guangdong, Kina, 510180
        • Research Site
      • Guangzhou, Guangdong, Kina, 510515
        • Research Site
    • Guangxi
      • Nanning, Guangxi, Kina, 530021
        • Research Site
    • Guizhou
      • Guiyang, Guizhou, Kina, 550004
        • Research Site
    • Hebei
      • Shijiazhuang, Hebei, Kina, 050000
        • Research Site
    • Heilongjiang
      • Harbin, Heilongjiang, Kina, 150001
        • Research Site
    • Henan
      • Zhengzhou, Henan, Kina, 450003
        • Research Site
      • Zhengzhou, Henan, Kina, 450052
        • Research Site
      • Zhengzhou, Henan, Kina, 463599
        • Research Site
    • Hubei
      • Wuhan, Hubei, Kina, 430030
        • Research Site
      • Wuhan, Hubei, Kina, 430000
        • Research Site
    • Hunan
      • Changsha, Hunan, Kina, 410008
        • Research Site
      • Changsha, Hunan, Kina, 410005
        • Research Site
    • Jiangsu
      • Nanjing, Jiangsu, Kina, 210029
        • Research Site
      • Nantong, Jiangsu, Kina, 226001
        • Research Site
      • Xuzhou, Jiangsu, Kina, 221002
        • Research Site
    • Jiangxi
      • Nanchang, Jiangxi, Kina, 330006
        • Research Site
      • Nanchang, Jiangxi, Kina, 330008
        • Research Site
    • Jilin
      • Changchun, Jilin, Kina, 130021
        • Research Site
    • Liaoning
      • Shenyang, Liaoning, Kina, 110001
        • Research Site
    • Shandong
      • Jinan, Shandong, Kina, 250000
        • Research Site
      • Qingdao, Shandong, Kina, 266000
        • Research Site
      • Zibo, Shandong, Kina, 255090
        • Research Site
    • Shangdong
      • Linyi, Shangdong, Kina, 276034
        • Research Site
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Kina, 200040
        • Research Site
      • Shanghai, Shanghai Municipality, Kina, 200336
        • Research Site
    • Shanxi
      • Taiyuan, Shanxi, Kina, 030000
        • Research Site
      • Xi’an, Shanxi, Kina, 710061
        • Research Site
      • Xi’an, Shanxi, Kina, 710068
        • Research Site
    • Sichuan
      • Chengdu, Sichuan, Kina, 610041
        • Research Site
      • Chengdu, Sichuan, Kina, 610072
        • Research Site
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Kina, 300020
        • Research Site
      • Tianjin, Tianjin Municipality, Kina, 300052
        • Research Site
      • Tianjin, Tianjin Municipality, Kina, 300190
        • Research Site
    • Yunnan
      • Kunming, Yunnan, Kina, 650034
        • Research Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Study Population:

Number of patients (estimate): 1000; Inclusion Criteria

  1. Patients of any age;
  2. Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
  3. Patient or patient's family must be willing and able to give written informed consent.

Exclusion Criteria

  1. Current or previous treatment with a non-eculizumab complement inhibitor;
  2. Patients in other PNH clinical trials.
  3. Unable to give written informed consent.

Beskrivelse

Inclusion Criteria

  1. Patients of any age;
  2. Diagnosed PNH with detected proportion of PNH clone cells of at least 1%;
  3. Patient or patient's family must be willing and able to give written informed consent.

Exclusion Criteria

  1. Current or previous treatment with a non-eculizumab complement inhibitor;
  2. Patients in other PNH clinical trials.
  3. Unable to give written informed consent.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Observasjonsmodeller: COHORT
  • Tidsperspektiver: PROSPECTIVE

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Hemolysis:Concentration of LDH changes at each visit from base-line, of all patients
Tidsramme: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with thrombosis within follow-up
Tidsramme: 12 months

To characterize the progression of PNH

12 months
average number of units of packed RBCs transfused per month, of all patients
Tidsramme: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with renal failure within follow-up
Tidsramme: 12 months

To characterize the progression of PNH

12 months
Number and percentage of patients with pulmonary hypertension within follow-up
Tidsramme: 12 months

To characterize the progression of PNH

12 months

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number and percentage of patients with each symptom of interest within follow-up
Tidsramme: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Demographics at baseline of all patients
Tidsramme: baseline

To describe clinical characteristics of patients with PNH in China

baseline
Number and percentage of patients receiving each type of treatment method at baseline and each visit within follow up, including glucocorticoid, red blood cell transfusion, other supportive treatment, bone marrow transplant, eculizumab, of all patients
Tidsramme: 12 months

To describe the treatment pattern of PNH in China

12 months
All serious adverse events (SAEs)of PNH among eculizumab-treated patients
Tidsramme: 12 months

To describe the safety of Eculizumab treatment via Serious Adverse Events

12 months
Standard descriptive statistics of pregnancy status
Tidsramme: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of lactation status
Tidsramme: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of PNH classification
Tidsramme: 12 months

To describe clinical characteristics of patients with PNH in China

12 months
Standard descriptive statistics of flow cytometry results
Tidsramme: 12 months

To describe clinical characteristics of patients with PNH in China

12 months

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Concentration of LDH changes at each visit from base-line of PNH among eculizumab-treated patients
Tidsramme: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with thrombosis within follow up among eculizumab-treated patients
Tidsramme: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
average number of units of packed RBCs transfused per month within 12 months v
Tidsramme: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with renal failure within follow up among eculizumab-treated patients
Tidsramme: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months
Number and percentage of patients with pulmonary hypertension (PH) within follow up among eculizumab-treated patients
Tidsramme: 12 months

Exploratory objective: To characterize the progression of PNH among eculizumab-treated patients

12 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

10. november 2023

Primær fullføring (Faktiske)

3. desember 2025

Studiet fullført (Faktiske)

3. desember 2025

Datoer for studieregistrering

Først innsendt

30. oktober 2023

Først innsendt som oppfylte QC-kriteriene

23. november 2023

Først lagt ut (Faktiske)

4. desember 2023

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

24. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

22. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

IPD-delingstidsramme

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Tilgangskriterier for IPD-deling

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere